Drugs / Neoantigen mRNA Personalised Cancer vaccine
Neoantigen mRNA Personalised Cancer vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05949775 | Jul 2023 → Dec 2025 | cancer | Stemirna Therapeutics | Unknown | No outcome recorded |
| — | NCT05761717 | Apr 2023 → Mar 2025 | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen mRNA Personalised Cancer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05761717 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA personalized tumor vaccine” NCT05761717 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection” NCT05761717 ↗ |